Crizotinib
别名: PF-02341066
目录号:S1068 Purity: 99.9%
Crizotinib克唑替尼是一种有效的c-Met和ALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂,其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。
CAS: 877399-52-5
客户使用Selleck的Crizotinib发表文献444篇
- Cancer Discov, 2024 OF1-OF20.
- Cancer Discov, 2023 13(3):598-615
- Cancer Cell, 2022 S1535-6108(21)00662-0
- Nat Cancer, 2022 3(6):710-722
- Nature, 2021 600(7888):319-323
- Cell, 2021 184(10):2649-2664.e18
- Signal Transduct Target Ther, 2021 6(1):401
- Cancer Cell, 2020 13;37(1):104-122e12
- Cancer Discov, 2020 1 pii: CD-19-1030
- J Thorac Oncol, 2020 15(5):752-765
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(2):179-193
- J Thorac Oncol, 2019 14(10):1753-1765
- Nat Med, 2018 24(7):968-977
- Cell, 2018 174(4):856-869
- Cancer Cell, 2018 34(6):922-938
- Cancer Discov, 2018 8(6):714-729
- Nat Biomed Eng, 2018 2(8):578-588
- J Thorac Oncol, 2017 S1556-0864(17)30365-9
- Nature, 2016 30;534(7609):647-51.
- J Clin Oncol, 2016 34(8):794-802
- Cancer Discov, 2016 6(12):1334-1341
- J Thorac Oncol, 2016 11(8):1273-1281
- Blood, 2016 128(9):1234-45
- Nat Med, 2015 21(9):1038-47
- Cell, 2015 162(6):1271-85
- Cancer Cell, 2015 27(3):397-408
- Cancer Cell, 2015 27(4):533-46
- Cell Res, 2015 10.1038/cr.2015.16
- Cancer Discov, 2015 5(9):960-971
- Cancer Discov, 2015 10.1158/2159-8290.CD-15-0913
- Cancer Discov, 2015
- Blood, 2015 126(26):2821-31
- Cancer Cell, 2014 26(2):207-21
- Cancer Discov, 2014 4(12):1398-405
- J Thorac Oncol, 2014 9(11):1638-46
- J Thorac Oncol, 2014 9(6):775-83
- Nat Med, 2013 19(11):1469-1472
- Nat Med, 2012 18(6):883-91
- Nature, 2012 487(7408):505-9
- Cell, 2012 151(5):937-50
- Nat Med, 2011 17(9):1116-20
- Cancer Cell, 2011 19(5):679-90
- Nat Commun, 2024 15(1):1009
- Nat Commun, 2024 15(1):51
- Adv Sci (Weinh), 2024 11(20):e2306059
- Cell Rep Med, 2024 5(3):101471
- Exp Hematol Oncol, 2024 13(1):97
- Br J Cancer, 2024
- Oncogene, 2024 10.1038/s41388-024-02987-5
- Commun Biol, 2024 7(1):412
- Transl Oncol, 2024 44:101939
- Sci Rep, 2024 14(1):22191
- Cancer Med, 2024 13(21):e70082
- BMC Cancer, 2024 24(1):357
- Clin Proteomics, 2024 21(1):3
- Exp Cell Res, 2024 442(2):114266
- PLoS One, 2024 19(5):e0300644
- PLoS One, 2024 19(6):e0304914
- Nat Commun, 2023 14(1):2829
- Nat Commun, 2023 14(1):3560
- Nat Commun, 2023 14(1):2601
- Adv Sci (Weinh), 2023 10(7):e2205262
- Clin Cancer Res, 2023 29(7):1317-1331
- Clin Cancer Res, 2023 29(5):943-956
- J Exp Clin Cancer Res, 2023 42(1):120
- J Exp Clin Cancer Res, 2023 10.1186/s13046-023-02866-z
- Cancer Res, 2023 83(19):3237-3251
- Cell Death Dis, 2023 14(7):463
- Br J Cancer, 2023 128(12):2186-2196
- EMBO Rep, 2023 24(7):e56937
- J Transl Med, 2023 21(1):530
- Front Immunol, 2023 14:1257017
- Mol Oncol, 2023 10.1002/1878-0261.13397
- Cells, 2023 12(3)483
- Cancer Metab, 2023 11(1):20
- Cancer Sci, 2023 114(1):164-173
- Int J Mol Sci, 2023 24(9)7730
- Biomolecules, 2023 13(3)438
- Cancers (Basel), 2023 16(1)9
- Cancers (Basel), 2023 15(18)4635
- Cancers (Basel), 2023 15(20)5089
- Cancers (Basel), 2023 15(13)3408
- Front Oncol, 2023 13:1184900
- Front Med (Lausanne), 2023 10:1149918
- bioRxiv, 2023 2023.03.03.531059
- Cancer Res Commun, 2023 3(12):2608-2622
- Cancer Res Commun, 2023 3(4):659-671
- Cell Rep Med, 2022 3(1):100492
- J Exp Clin Cancer Res, 2022 41(1):309
- Cancer Res, 2022 CAN-22-0770
- Cell Death Dis, 2022 13(4):351
- Cell Rep, 2022 41(11):111827
- Eur J Cancer, 2022 170:91-102
- Cell Mol Life Sci, 2022 80(1):6
- NPJ Precis Oncol, 2022 6(1):5
- Biomed Pharmacother, 2022 158:114162
- Breast Cancer Res, 2022 24(1):41
- Mol Cell Proteomics, 2022 S1535-9476(22)00071-8
- Cell Oncol (Dordr), 2022 45(4):601-619
- iScience, 2022 25(10):105182
- Front Pharmacol, 2022 13:1032975
- Lung Cancer, 2022 171:103-114
- Cancers (Basel), 2022 14(9)2176
- Cancers (Basel), 2022 14(24)6201
- Mol Cancer Res, 2022 molcanres.MCR-22-0025-E.2022
- Cancers (Basel), 2022 14(6)1378
- Mol Cancer Res, 2022 20(6):854-866
- J Pers Med, 2022 12(2)258
- J Biol Chem, 2022 S0021-9258(22)00070-9
- Front Oncol, 2022 12:713476
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Transl Lung Cancer Res, 2022 11(11:2216-2229)
- Transl Lung Cancer Res, 2022 11(5):786-801
- BMC Cancer, 2022 22(1):752
- Mol Pharmacol, 2022 MOLPHARM-AR-2021-000287
- Clin Transl Oncol, 2022 10.1007/s12094-022-02884-x
- Clin Transl Oncol, 2022 10.1007/s12094-022-02835-6
- Thorac Cancer, 2022 10.1111/1759-7714.14372
- Thorac Cancer, 2022 13(21):3032-3041.
- Environ Mol Mutagen, 2022 63(3):151-161
- Acta Histochem, 2022 124(4):151895
- Anticancer Drugs, 2022 10.1097/CAD.0000000000001344
- Anticancer Drugs, 2022 33(2):124-131
- Cold Spring Harb Mol Case Stud, 2022 8(6)a006222
- Cancer Res Commun, 2022 2(5):277-285
- Nat Commun, 2021 12(1):6813
- Nat Commun, 2021 12(1):5006
- Cancer Res, 2021 81(23):5935-5947
- Angiogenesis, 2021 10.1007/s10456-021-09771-z
- Cancer Lett, 2021 522:119-128
- NPJ Precis Oncol, 2021 5(1):78
- NPJ Precis Oncol, 2021 5(1):91
- Cell Oncol (Dordr), 2021 10.1007/s13402-021-00632-x
- Oncogenesis, 2021 10(3):25
- Oncogenesis, 2021 10(3):27
- NPJ Breast Cancer, 2021 7(1):60
- Biochem Pharmacol, 2021 190:114620
- Cancer Sci, 2021 112(5):1853-1864
- Mol Cancer Ther, 2021 molcanther.0371.2021
- Mol Cancer Ther, 2021 molcanther.0344.2021
- Mol Cancer Ther, 2021 molcanther.0221.2021
- Mol Cancer Ther, 2021 20(9):1653-1662
- J Mol Biol, 2021 433(19):167158
- J Mol Biol, 2021 S0022-2836(21)00531-3
- Int J Mol Sci, 2021 23(1)395
- J Cell Mol Med, 2021 10.1111/jcmm.17037
- Cancers (Basel), 2021 13(3)E372
- Cancers (Basel), 2021 13(21)5474
- Cancers (Basel), 2021 13(16)4133
- Front Oncol, 2021 11:650052
- Development, 2021 148(18)dev199706
- Sci Rep, 2021 11(1):9011
- Sci Rep, 2021 11(1):12466
- Mol Carcinog, 2021 60(7):481-496
- Sci Rep, 2021 11(1):9587
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Onco Targets Ther, 2021 14:4809-4817
- J Cancer, 2021 12(21):6356-6362
- Drug Metab Dispos, 2021 49(1):53-61
- Endocr Relat Cancer, 2021 28(6):377-389
- BMC Cancer, 2021 21(1):310
- Acta Biochim Biophys Sin (Shanghai), 2021 53(7):823-836
- Ann Hematol, 2021 10.1007/s00277-020-04357-z
- Genes (Basel), 2021 12(5)742
- Thorac Cancer, 2021 10.1111/1759-7714.14184
- STAR Protoc, 2021 2(4):100822
- Nat Commun, 2020 11(1):5704
- Nat Commun, 2020 11(1):5017
- Nat Commun, 2020 25;11(1):1556
- Genome Med, 2020 18;12(1):17
- Dev Cell, 2020 4;53(3):344-357 e5
- Clin Cancer Res, 2020 10.1158/1078-0432.CCR-19-3608
- Clin Cancer Res, 2020 8
- Clin Cancer Res, 2020 clincanres.2853.2020
- Clin Cancer Res, 2020 10.1158/1078-0432
- Cancer Res, 2020 canres.1992.2020
- EMBO Mol Med, 2020 e11099
- Int J Biol Sci, 2020 16(14):2595-2611
- Cell Death Dis, 2020 11(10):882
- Br J Cancer, 2020 10.1038/s41416-020-0952-1
- Acta Pharmacol Sin, 2020 10.1038/s41401-020-00513-3
- NPJ Precis Oncol, 2020 4:21
- Antiviral Res, 2020 178:104790
- Blood Adv, 2020 4(5):819-829
- Front Immunol, 2020 11:527750
- Hemasphere, 2020 4(6):e497
- Oncogenesis, 2020 9(7):64
- Cancer Cell Int, 2020 19;20:58
- Cancer Cell Int, 2020
- Cancer Sci, 2020 111(10):3813-3823
- J Cell Physiol, 2020 10.1002/jcp.29463
- Int J Mol Sci, 2020 21(23)8904
- Int J Mol Sci, 2020 18;21(8):2825
- Lung Cancer, 2020 144:20-29
- Am J Cancer Res, 2020 10(2):403-423
- Cancers (Basel), 2020 27;12(5)pii: E1087
- Cancers (Basel), 2020 13;12(2) pii: E436
- Mol Cancer Res, 2020 18(4):549-559
- Cancers (Basel), 2020 12(9)E2697
- Oral Oncol, 2020 112:105074
- J Biol Chem, 2020 jbc.RA120.015891
- Neoplasia, 2020 22(10):470-483
- Sci Rep, 2020 10(1):218
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Oncol Rep, 2020 43(3):817-826
- J Cell Sci, 2020 11;133(9) pii: jcs241505
- Transl Lung Cancer Res, 2020 9(5):1810-1821
- Transl Lung Cancer Res, 2020 9(5):1904-1914
- Biomed Res Int, 2020 2020:2046248
- Anticancer Res, 2020 40(1):109-119
- Anticancer Res, 2020 40(3):1395-1403
- Sci Adv, 2020 22;6(21):eaaz8521
- Nat Commun, 2019 10(1):3991
- Nat Commun, 2019 10(1):4343
- Nat Commun, 2019 10(1):2532
- Clin Cancer Res, 2019 clincanres.1486.2019
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-1104
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-1667
- Clin Cancer Res, 2019 10.1158/1078-0432
- Cancer Res, 2019 79(3):546-556
- EBioMedicine, 2019 42:326-339
- EMBO Mol Med, 2019 10.15252/emmm.201910581
- Cancer Immunol Res, 2019
- Cell Death Dis, 2019 10(9):663
- Cell Death Dis, 2019 10(2):139
- Cell Rep, 2019 28(9):2331-2344
- Cell Rep, 2019 26(1):65-78
- Oncogene, 2019 101038/s41388-019-1136-4
- Oncogene, 2019 38(11):1936-1950
- Cells, 2019 8(12)
- Biochem Pharmacol, 2019 166:128-138
- Mol Cancer Ther, 2019 18(3):718-725
- Cancer Sci, 2019 110(11):3584-3594
- Int J Mol Sci, 2019 20(17)
- Oncotarget, 2019 10(65):6981-6996
- Cancers (Basel), 2019
- Cancers (Basel), 2019 11(9)
- Cancers (Basel), 2019 11(1)E104
- Transl Oncol, 2019 12(1):116-121
- Front Oncol, 2019 9:579
- Front Oncol, 2019 9:579
- Molecules, 2019 24(3)
- Cancer Res Treat, 2019 51(3):1231-1240
- Sci Rep, 2019 9(1):19353
- Cancer Res Treat, 2019 51(3):951-962
- Sci Rep, 2019
- Toxicol Appl Pharmacol, 2019 383:114768
- BMC Cancer, 2019 19(1):1044
- Toxicol Sci, 2019 10.1093/toxsci/kfz123
- Invest New Drugs, 2019 10.1007/s10637-019-00795-3
- Future Oncol, 2019 15(22):2585-2593
- Biochem Biophys Res Commun, 2019 511(2):260-265
- Leuk Res, 2019 78:12-20
- Cancer Commun (Lond), 2018 38(1):19
- J Clin Invest, 2018 128(9):4086-4097
- J Clin Invest, 2018 128(1):446-462
- Nat Chem Biol, 2018 14(8):768-777
- Cell Death Differ, 2018 25(12):2053-2070
- Clin Cancer Res, 2018 24(17):4162-4174
- Clin Cancer Res, 2018 24(12):2732-2739
- Clin Cancer Res, 2018 24(23):6066-6077
- Clin Cancer Res, 2018 24(13):3126-3136
- Leukemia, 2018 32(9):1994-2007
- Proc Natl Acad Sci U S A, 2018 115(26):E6030-E6038
- Cell Syst, 2018 6(3):329-342
- Cell Death Dis, 2018 9(10):974
- Cell Death Dis, 2018 9(3):262
- Sci Signal, 2018 11(557)
- Sci Signal, 2018 11(557)eaar5680
- Cancer Gene Ther, 2018 26(1-2):1-10
- Mol Cancer Ther, 2018 17(11-:2271-2284
- Cancer Sci, 2018 109(10):3149-3158
- Mol Cancer Ther, 2018 17(3):603-613
- Mol Cancer Ther, 2018 17(12):2622-2632
- Mol Cancer Ther, 2018 17(5):931-942
- Mol Cancer Ther, 2018 17(1):222-231
- Oncotarget, 2018 9(43-:27242-27255
- Am J Cancer Res, 2018 8(8):1541-1550
- Am J Cancer Res, 2018 8(1):183-191
- Mol Pharm, 2018 15(5):1892-1900
- Front Oncol, 2018 8:460
- Sci Rep, 2018
- Cancer Res Treat, 2018 50(2):599-613
- J Proteome Res, 2018 17(1):63-75
- Endocr Relat Cancer, 2018 25(4):471-480
- Pediatr Blood Cancer, 2018 65(8):e27094
- Cancer Chemother Pharmacol, 2018 82(2):251-263
- Oncol Lett, 2018 16(5):5983-5991
- Oncol Lett, 2018 16(5):5992-5996
- Oncolytic Virother, 2018 7:107-116
- Nat Chem Biol, 2017 13(6):681-690
- Cancer Res, 2017 77(13):3551-3563
- Cancer Res, 2017 77(13):3502-3512
- Cell Death Dis, 2017 8(8):e3013
- Br J Cancer, 2017 117(12):1787-1797
- Cell Rep, 2017 21(11):3298-3309
- Oncogene, 2017
- Oncogene, 2017 36(38):5407-5420
- J Pathol, 2017 243(3):307-319
- Arch Toxicol, 2017 91(8):2921-2938
- Oncologist, 2017 22(2):158-164
- Mol Cancer Ther, 2017 16(10):2234-2245
- Oncotarget, 2017 8(35):58771-58780
- Oncotarget, 2017 8(70):114945-114955
- Oncotarget, 2017 8(31):51675-51687
- Am J Cancer Res, 2017 7(2):203-217
- Mol Cancer Res, 2017 15(1):106-114
- Molecules, 2017 22(12)
- Sci Rep, 2017 7:44206
- BMC Cancer, 2017 17(1):191
- BMC Cancer, 2017
- Medchemcomm, 2017 8(10):1914-1918
- SLAS Discov, 2017 22(5):507-515
- Oncol Lett, 2017 13(6):4085-4092
- Cardiooncology, 2017 10.1186/s40959-017-0020-z
- Nat Commun, 2016 7:11815
- Nat Commun, 2016 7:10690
- J Clin Invest, 2016 3;126(10):3739-3757
- Int J Surg, 2016 28:179-84
- Genome Biol, 2016 17:80
- Clin Cancer Res, 2016 22(7):1787-99
- Clin Cancer Res, 2016 22(22):5527-5538
- Clin Cancer Res, 2016 22(24):6031-6038
- Cancer Res, 2016 76(6):1506-16
- Cancer Res, 2016 76(13):3895-903
- Cancer Res, 2016 76(4):974-83
- Elife, 2016 5e12116
- J Pathol, 2016 238(4):543-9
- Oncoimmunology, 2016 5(3):e1094598
- Mol Cancer Ther, 2016 15(12):3040-3054
- Oncotarget, 2016 7(51):84675-84687
- Oncotarget, 2016 7(46):75968-75980
- Oncotarget, 2016 7(5):5646-63
- Oncotarget, 2016 7(18-:25983-6002
- Oncotarget, 2016 7(20):29199-210
- Oncotarget, 2016 7(17):23715-29
- Int J Oncol, 2016 49(6):2453-2463
- Int J Oncol, 2016 49(6):2236-2244
- Mol Pharm, 2016 13(11):3724-3735
- Cellular Signalling, 2016 19;28(6):652-662
- Sci Rep, 2016 10.1038/srep24817
- Sci Rep, 2016 6:32992
- PLoS One, 2016 11(11):e0165983
- Endocrine, 2016
- Cancer Chemother Pharmacol, 2016 77(3):623-8
- Vet Parasitol, 2016 227:64-8
- Springerplus, 2016 5:348
- World J Clin Oncol, 2016 7(6):425-432
- Tumour Biol, 2016 37(4):4373-82
- Chinese Pharmacological Bulletin, 2016 32(9): 1284-1288
- Nat Commun, 2015 6:7002
- Cancer Res, 2015 10.1158/0008-5472.CAN-15-0370
- Cancer Res, 2015 75(14):2916-27
- Elife, 2015
- Oncoimmunology, 2015 5(3):e1108514
- Cancer Sci, 2015 106(3):244-52
- Radiother Oncol, 2015
- Mol Cancer Ther, 2015 14(11-:2433-40
- J Cell Physiol, 2015 230(9):2281-98
- Oncotarget, 2015 6(31):31640-58
- Oncotarget, 2015 6(27):24320-32
- Oncotarget, 2015 6(14):11820-32
- Oncotarget, 2015
- Oncotarget, 2015 6(37):40268-82
- Oncotarget, 2015 6(30):28774-89
- Lung Cancer, 2015 90(3):590-7
- Int J Oncol, 2015 46(3):1025-30
- Int J Oncol, 2015 47(1):122-32
- PLoS Genet, 2015 11(9):e1005533
- Onco Targets Ther, 2015 8:375-83
- Toxicol Appl Pharmacol, 2015 285(1):51-60
- BMC Cancer, 2015 15:451
- PLoS One, 2015 10(7):e0132330
- PLoS One, 2015 10(4):e0124283
- PLoS One, 2015 10(4):e0121378
- Biochem Biophys Res Commun, 2015 10.1016/j.bbrc.2015.02.114
- Zhongguo Fei Ai Za Zhi, 2015 18(6):330-9
- Clin Cancer Res, 2014 20(11):2898-909
- Clin Cancer Res, 2014 20(18):4806-15
- Proc Natl Acad Sci USA, 2014 111(44):E4706-15
- Cancer Lett, 2014 351(2):215-21
- Cell Rep, 2014 8(4):1037-48
- Elife, 2014 10.7554/eLife.03751
- Gastric Cancer, 2014 10.1007/s10120-014-0444-1
- Mol Oncol, 2014 9(1):260-9
- Cancer Sci, 2014 105(5):528-36
- Mol Cancer Ther, 2014 13(1):134-43
- Mol Cancer Ther, 2014 10.1158/1535-7163.MCT-14-0274
- Oncotarget, 2014 5(13):4920-8
- Cell Cycle, 2014
- PLoS One, 2014 9(9):e105919
- PLoS One, 2014 9(11):e112148
- PLoS One, 2014 9(10):e111146
- Biomed Res Int, 2014 2014:764981
- J Cancer Res Clin Oncol, 2014 140(4):589-98
- Future Oncol, 2014 10(2):211-7
- Cancer Chemother Pharmacol, 2014 74(5):1023-8
- Leuk Res, 2014 38(4):503-8
- Urol Oncol, 2014 32(6):877-84
- Jpn J Clin Oncol, 2014 44(10):963-8
- Assay Drug Dev Technol, 2014 12(9-10):514-26
- Korean J Parasitol, 2014 52(4):439-41
- Exp Mol Med, 2013 45:e64
- Clin Cancer Res, 2013 19(9):2584-91
- Clinical Cancer Research, 2013 19(9)
- Br J Cancer, 2013 109(12):3084-91
- Clin Chem Lab Med, 2013 51(9):1843-8
- Mol Oncol, 2013 7(6):1093-102
- Int J Cancer, 2013 133(2):427-36
- Int J Cancer, 2013 132(2):E74-84
- Cancer Sci, 2013 104(12):1640-6
- Cancer Sci, 2013 104(12):1618-25
- J Am Heart Assoc, 2013 2(6):e000376
- Oncotarget, 2013 4(12):2237-48
- Sci Rep, 2013 3:3450
- Molecules, 2013 18(12):15412-21
- PLoS Genet, 2013 9(11):e1003958
- ACS Chem Biol, 2013 9(3):777-84
- J Cell Biochem, 2013 114(4):816-22
- Toxicol Appl Pharmacol, 2013 272(1):245-55
- PLoS One, 2013 8(12):e82236
- PLoS One, 2013 8(2):e56010
- PLoS One, 2013 8(12):e84700
- Mol Pharmacol, 2013 83(4):882-93
- Int J Cardiol, 2013 168(4):3486-94
- Springerplus, 2013 2:497
- Tumour Biol, 2013 35(4):3229-35
- CELON PHARMA, 2013 2013
- Sci Transl Med, 2012 4(120):120ra17
- Br J Pharmacol, 2012 166(5):1669-83
- J Biol Chem, 2012 287(18):14586-97
- J Biol Chem, 2012 287(47):39812-23
- Neoplasia, 2012 14(7):572-84
- ACS Chem Biol, 2012 7(8):1429-35
- PLoS One, 2012 7(2):e30820
- Pediatr Blood Cancer, 2012 17(23):7394-401
- Clin Cancer Res, 2011 17(23):7394-401
- Cancer Res, 2011 71(15):5255-64
- J Biomol Screen, 2011 16(2):141-54
- Int J Proteomics, 2011 2011:215496
化学信息&溶解度
分子量 | 450.34 |
分子式 | C21H22Cl2FN5O |
CAS号 | 877399-52-5 |
Smiles | CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 25 mg/mL ( 55.51 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 23 mg/mL ( 51.07 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 90 mg/mL ( 199.84 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
10%DMSO
90%Corn oil
浓度:2.5mg/ml
(5.55mM)
操作示例:以 1 mL 工作液为例,取100μL25mg/ml的澄清DMSO储备液加到900μL玉米油中,混合均匀。工作液请现配现用!
|
|
5%DMSO
40%PEG300
10%Tween80
45%ddH2O
浓度:2.5mg/ml
(5.55mM)
操作示例:以 1 mL 工作液为例,取50 μL 50mg/ml的澄清DMSO储备液加到400 μL PEG300中,混合均匀使其澄清;向上述体系中加入100 μL Tween80,混合均匀使其澄清;然后继续加入450 μL ddH2O定容至1mL。工作液请现配现用!
|
|
5%DMSO
Corn oil
浓度:4.5mg/ml
(9.99mM)
操作示例:以 1 mL 工作液为例,取50μL90mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。